Impiricus is a company that provides an AI-powered engagement platform for the healthcare industry, connecting pharmaceutical companies, medical device makers, and other life sciences companies with healthcare professionals (HCPs) to improve patient outcomes. Pulse 2.0 interviewed Impiricus co-founder and Chief Product Officer Dr. Osama Hashmi to gain a deeper understanding of the company.
Dr. Osama Hashmi’s Background
What does Dr. Osama Hashmi do? Dr. Hashmi said:
“I’m a board-certified dermatologist and entrepreneur with a deep passion for transforming healthcare through technology. My journey began in clinical practice, where I served as Chief Resident of Dermatology at Emory University. During my time there I realized that many of the inefficiencies in healthcare could be solved with the right technological tools. That realization, in combination with experience and the launch of several healthcare ventures, including a teledermatology company and a patient engagement platform, led to my leadership positions in initiatives to improve patient intake and clinical efficiency. Today, I serve as CEO and co-founder of Impiricus, where we’re redefining how healthcare professionals engage with pharmaceutical companies.”
Formation Of The Company
How did the idea for the company come together? Dr. Hashmi shared:
“The idea for Impiricus was born out of a persistent challenge I observed in both clinical practice and industry: the disconnect between healthcare professionals and pharmaceutical manufacturers. Traditional engagement methods were outdated, inefficient, and often mistrusted, and I viewed it as an opportunity to build a trusted, tech-enabled channel that could deliver relevant, personalized, and timely information to HCPs. Over three years, I assembled a world-class team of physicians, pharma experts, and technologists to bring this vision to life.”
Favorite Memory
What has been your favorite memory working for the company so far? Dr. Hashmi reflected:
“One of my favorite memories has been watching Impiricus grow from just myself and my co-founder, Sandy, into an A+ team of experts across product, partnerships, client services, data, engineering, operations, and more. Building this team has been one of the most rewarding parts of the journey, as each person brings not only deep expertise but also a shared passion for transforming healthcare. Seeing our collective vision come to life through the buy-in of our HCP network is so powerful. Major pharmaceutical companies have told us, “Impiricus is redefining our go-to-market model”, proving that great teams build great companies, and I’m incredibly proud of the culture and impact we’ve created together.”
Core Products
What are the company’s core products and features? Dr. Hashmi explained:
“Impiricus is the first and only AI-powered HCP Engagement Engine. Founded by me, a physician, and Sandy Donaldson, a pharmaceutical executive, Impiricus was created to cut through the noise and put physician care delivery at the forefront. With our unique frontline access to over 1 million HCPs, their insights, and clinical expertise, we are committed to providing life science companies with innovative channels and AI technology needed to deliver clear, reliable, and evidence-based resources directly into the hands of HCPs. Guided by a council of 2000+ trusted HCP advisors, we ensure every product and touchpoint truly reflects the needs of clinicians and leads to better patient care.
Our core products include:
Pulse: Flighted delivery of value-added content to target and white-space HCPs
Spark: Personalized trigger-based messaging powered by marketing or clinical activity
Ascend: AI-enabled and integrated 2-way experiences for HCPs that deeply connect them to pharma brand resources in real time.
Our real-time channels achieve 98% open rates, often within minutes, and reach about 30% “white space” healthcare providers, also known as those unreachable by traditional methods.
Key features include:
— AI-driven personalization
— Specialty-specific targeting
— Real-time analytics
— Physician-led content curation
— Global opt-out rates below 0.1%”
Challenges Faced
What challenges have Dr. Hashmi and the team faced in building the company? Dr. Hashmi acknowledged:
“Yes, one of the most persistent challenges we’ve faced is the widespread inefficiency in how pharmaceutical companies engage with healthcare professionals. The industry has long relied on outdated tactics, like rep visits, overloaded portals, and mass email campaigns, that no longer align with how physicians prefer to learn or interact. These legacy strategies collectively waste an estimated $38 billion annually, creating a massive blind spot that directly impacts drug adoption and revenue. This leads to high skepticism from HCPs toward pharma engagement.”
“At Impiricus, we’ve tackled this challenge head-on by reimagining HCP engagement from the ground up. We build trust through physician-led design, transparent data practices, and a relentless focus on impact. We built a platform that leverages AI-powered, real-time channels to reach physicians where they are, with content that’s relevant to their specialty and clinical needs. We invest in automation, robust infrastructure, and a culture of continuous improvement.”
“This transformation wasn’t just technological; it required cultural change across the industry. We’ve worked closely with pharma leaders to shift engagement from a brand-level marketing exercise to a C-suite priority, integrating digital and in-person channels, redefining KPIs, and training hybrid sales teams to use data-driven insights. The results speak for themselves: smarter engagement is now driving measurable impact on both the balance sheet and patient outcomes.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Dr. Hashmi noted:
“Our technology has evolved from basic SMS outreach tools to sophisticated AI-driven platforms that deliver hyper-personalized content. We’ve integrated machine learning to optimize engagement timing, content relevance, and channel selection. Our platform now supports dynamic feedback loops, allowing us to continuously refine our approach based on physician behavior and preferences.”
Significant Milestones
What have been some of the company’s most significant milestones? Dr. Hashmi cited:
— Growing 30,000% from 2021 to 2024
— Serving over 1 million HCPs
— Partnering with all top 20 pharmaceutical companies
— Achieving up to 27:1 ROI on campaigns
— Being recognized as a leading workplace and fastest-growing AI engagement solution in healthcare
Customer Success Stories
When asking Dr. Hashmi about customer success stories, he highlighted:
“One of our oncology clients used Impiricus to reach previously inaccessible “white-space” prescribers. The campaign achieved a 145% lift in prescriptions, getting more patients onto life-saving treatment. For another partner, we reached low-see Dermatologists outside of what their reps could cover, driving $33 million in incremental revenue. On average, our pharma partners see a 90% relevance from physicians, with engagement rates that exceed industry norms by 6 times. This is proof that when content is timely and personalized, physicians respond.”
“But the impact goes beyond metrics to patient care. One example, we helped a patient who was paying $2,000–$3,000 every time they went to CVS for their medication. After six months of battling with insurance, the best price they were offered was $800. Through our channels, we helped their physician discover that the pharmaceutical company actually had a special pharmacy program where the same medication was available for free. The issue wasn’t the drug manufacturer, it was the insurance company acting as a bottleneck.”
“This is exactly why we focus on getting the right information to doctors at the right time. When you cut through the insurance red tape and connect physicians directly with the resources they need, patients get better care, and often at a fraction of the cost. These stories are a powerful reminder that smarter HCP engagement isn’t just good business, it’s better healthcare.”
Funding And Revenue
When asking Dr. Hashmi about the company’s funding and revenue details, he revealed:
“While we’re privately held and selective about what we disclose, I can share that our growth has been exponential—30,000% over three years—and our campaigns consistently deliver double-digit ROI. Our focus is always to look for the next opportunity to reinvest in product innovation and team expansion.”
Total Addressable Market
What total addressable market (TAM) size is the company pursuing? Dr. Hashmi assessed:
“We’re targeting a TAM of over $50 billion, which includes digital pharma marketing, HCP education, and AI-driven healthcare engagement. With over 1 million HCPs already on our platform, we’re just scratching the surface of what’s possible.”
Differentiation From The Competition
What differentiates the company from its competition? Dr. Hashmi affirmed:
“What sets Impiricus apart is our ability to combine clinical insight with cutting-edge technology to solve one of pharma’s most expensive and overlooked problems: inefficient physician engagement. While many companies offer digital tools or rep enablement platforms, we’ve built an AI-powered system that actually reaches and personally supports physicians—especially the 30% “white space” prescribers that reps and traditional channels consistently miss.”
“Our real-time channels achieve 98% open rates, 90%+ physician-reported relevance, and global opt-out rates below 0.1%, which are virtually unheard of in the industry. But it’s not just about metrics—it’s about trust. Our physician-led approach ensures that every interaction is clinically relevant, timely, and respectful of how HCPs prefer to engage. That’s why we’ve been able to build a network of over 1 million highly engaged HCPs and partner with all top 20 pharmaceutical companies.”
Future Company Goals
What are some of the company’s future goals? Dr. Hashmi emphasized:
“We aim to expand our network, deepen our AI capabilities, and continue building tools that empower HCPs and improve patient outcomes. A major focus moving forward is reaching underserved HCPs across the country, particularly community physicians who care for marginalized and underserved patient populations. These providers often operate with limited access to pharmaceutical resources, educational updates, and support programs—yet they serve some of the most vulnerable patients. By bridging this gap, we aim to empower these physicians with timely, actionable insights that can improve care quality and reduce costs for their patients.”
“We’re also expanding into new verticals, including clinical trial recruitment, patient affordability programs, and global physician engagement. Our goal is to make smarter HCP engagement not just a commercial advantage, but a catalyst for better healthcare outcomes across diverse communities.”
“Ultimately, we envision a future where every physician, regardless of location or practice setting, has access to the tools, education, and support they need to deliver the best possible care. And we’re building the technology to make that future a reality.”
Additional Thoughts
Any other topics you would like to discuss? Dr. Hashmi concluded:
“The importance of keeping innovation patient-centered should be top of mind for everyone in today’s market. Even as we scale and evolve, I continue to practice medicine because it keeps me grounded in the realities of patient care. That clinical perspective is what drives everything we do at Impiricus.”
